Central control of bone remodelling

Journal of Neuroendocrinology

Volumn 20, Issue 6, 2008, Pages 802-807

  Takeda, Shu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bone remodelling; Central nervous system; Leptin; Sympathetic nervous system

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOPRENALINE; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; NEUROMEDIN U; NUCLEAR FACTOR Y; OSTEOCLAST DIFFERENTIATION FACTOR; PROPRANOLOL; TRANSCRIPTION FACTOR;

ADRENERGIC SYSTEM; ANOREXIA; ARCUATE NUCLEUS; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; COMPLEX REGIONAL PAIN SYNDROME TYPE I; HIP FRACTURE; HUMAN; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; NEUROENDOCRINE SYSTEM; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE REMODELING; CANNABINOIDS; HUMANS; LEPTIN; NEUROPEPTIDES; SYMPATHETIC NERVOUS SYSTEM;

EID: 45549105599     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01732.x     Document Type: Review

References (49)

1. Cooper C, Melton LJI. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, CA: Academic Press, 1996: 419-434.
2. Karsenty G. Convergence between bone and energy homeostases: Leptin regulation of bone mass. Cell Metab 2006; 4: 341-348.
3. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109: 915-921.
4. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434: 514-520.
5. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, Fukumoto S, Fujita T, Kato S, Kangawa K, Kojima M, Shinomiya K, Takeda S. Central control of bone remodeling by neuromedin U. Nat Med 2007; 13: 1234-1240.
6. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-437.
7. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000; 100: 197-207.
8. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004; 5: 1007-1012.
9. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, Ogawa Y, Liu X, Ware SM, Craigen WJ, Robert JJ, Vinson C, Nakao K, Capeau J, Karsenty G. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 2004; 101: 3258-3263.
10. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002; 175: 405-415.
11. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Gordeladze JO, Drevon CA. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001; 16: 1426-1433.
12. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-1638.
13. Steppan C, Crawford D, Chidsey-Frink K, Ke H, Swick A. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000; 92: 73-78.
14. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner RT. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 2001; 142: 3546-3553.
15. Guidobono F, Pagani F, Sibilia V, Netti C, Lattuada N, Rapetti D, Mrak E, Villa I, Cavani F, Bertoni L, Palumbo C, Ferretti M, Marotti G, Rubinacci A. Different skeletal regional response to continuous brain infusion of leptin in the rat. Peptides 2006; 27: 1426-1433.
16. Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, Schinke T, Rueger JM, Schneider E, Clarke I, Amling M. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res 2006; 21: 1591-1599.
17. Ruhl CE, Everhart JE. Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res 2002; 17: 1896-1903.
18. Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R. Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 2001; 28: 113-117.
19. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 1998; 63: 456-458.
20. Thomas T, Burguera B, Melton LJ III, Atkinson EJ, O'Fallon WM, Riggs BL, Khosla S. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29: 114-120.
21. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6096.
22. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317.
23. Flier JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
24. Bray GA, York DA. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res 1998; 53: 95-117.
25. Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki H, Hosoda K, Yoshimasa Y, Nakao K. Sympathetic activation of leptin via the ventromedial hypothalamus: Leptin-induced increase in catecholamine secretion. Diabetes 1999; 48: 1787-1793.
26. Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 2005; 280: 30192-30200.
27. Sseur R, Sabatier JP, Potrel-Burgot C, Lecoq B, Creveuil C, Marcelli C. Sympathetic nervous system as transmitter of mechanical loading in bone. Joint Bone Spine 2003; 70: 515-519.
28. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus V, Shohami E, Bab I. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci USA 2006; 103: 16876-16881.
29. Marenzana M, De Souza RL, Chenu C. Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 2007; 41: 206-215.
30. Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 2006; 318: 1118-1127.
31. Kurvers HA. Reflex sympathetic dystrophy: Facts and hypotheses. Vasc Med 1998; 3: 207-214.
32. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E, Bab I. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008; 22: 285-294.
33. Wiens M, Etminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: A meta-analysis of observational studies. J Intern Med 2006; 260: 350-362.
34. Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, Kuhar MJ, Saper CB, Elmquist JK. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998; 21: 1375-1385.
35. Asnicar MA, Smith DP, Yang DD, Heiman ML, Fox N, Chen YF, Hsiung HM, Koster A. Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet. Endocrinology 2001; 142: 4394-4400.
36. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006; 27: 736-749.
37. Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 2006; 147: 3196-3202.
38. Guerardel A, Tanko LB, Boutin P, Christiansen C, Froguel P. Obesity susceptibility CART gene polymorphism contributes to bone remodeling in postmenopausal women. Osteoporos Int 2006; 17: 156-157.
39. Brighton PJ, Szekeres PG, Willars GB. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 2004; 56: 231-248.
40. Hanada R, Nakazato M, Murakami N, Sakihara S, Yoshimatsu H, Toshinai K, Hanada T, Suda T, Kangawa K, Matsukura S, Sakata T. A role for neuromedin U in stress response. Biochem Biophys Res Commun 2001; 289: 225-228.
41. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 2005; 122: 803-815.
42. Hainerova I, Torekov SS, Ek J, Finkova M, Borch-Johnsen K, Jorgensen T, Madsen OD, Lebl J, Hansen T, Pedersen O. Association between neuromedin U gene variants and overweight and obesity. J Clin Endocrinol Metab 2006; 91: 5057-5063.
43. Lin S, Boey D, Herzog H. NPY and Y receptors: Lessons from transgenic and knockout models. Neuropeptides 2004; 38: 189-200.
44. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ, Enriquez RF, McDonald MM, Zhang L, During MJ, Little DG, Eisman JA, Gardiner EM, Yulyaningsih E, Lin S, Sainsbury A, Herzog H. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007; 282: 19092-19102.
45. Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, Enriquez RF, Sainsbury A, Lamghari M, Simmons P, Eisman JA, Gardiner EM, Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007; 282: 19082-19091.
46. Sainsbury A, Baldock PA, Schwarzer C, Ueno N, Enriquez RF, Couzens M, Inui A, Herzog H, Gardiner EM. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 2003; 23: 5225-5233.
47. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11: 774-779.
48. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, Zimmer A, Mackie K, Mechoulam R, Shohami E, Bab I. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006; 70: 786-792.
49. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006; 103: 696-701.